COVID-19 Treatment—Current Status, Advances, and Gap
COVID-19, which emerged in December 2019, was declared a global pandemic by the World Health Organization (WHO) in March 2020. The disease was caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It has caused millions of deaths worldwide and caused social and economic disruption....
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | en en |
| Published: |
MDPI
2022
|
| Subjects: | |
| Online Access: | https://eprints.ums.edu.my/id/eprint/35232/1/Abstract.pdf https://eprints.ums.edu.my/id/eprint/35232/2/Full%20text.pdf https://eprints.ums.edu.my/id/eprint/35232/ https://www.mdpi.com/2076-0817/11/10/1201 https://doi.org/10.3390/pathogens11101201 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1831795524906254336 |
|---|---|
| author | Chian Ho Lee, Ping Chin |
| author_facet | Chian Ho Lee, Ping Chin |
| author_sort | Chian Ho |
| building | UMS Library |
| collection | Institutional Repository |
| content_provider | Universiti Malaysia Sabah |
| content_source | UMS Institutional Repository |
| continent | Asia |
| country | Malaysia |
| description | COVID-19, which emerged in December 2019, was declared a global pandemic by the World Health Organization (WHO) in March 2020. The disease was caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It has caused millions of deaths worldwide and caused social and economic disruption. While clinical trials on therapeutic drugs are going on in an Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) public–private partnership collaboration, current therapeutic approaches and options to counter COVID-19 remain few. Therapeutic drugs include the FDA-approved antiviral drugs, Remdesivir, and an immune modulator, Baricitinib. Hence, therapeutic approaches and alternatives for COVID-19 treatment need to be broadened. This paper discusses efforts in approaches to find treatment for COVID-19, such as inhibiting viral entry and disrupting the virus life cycle, and highlights the gap that needs to be filled in these approaches. |
| format | Article |
| id | my.ums.eprints-35232 |
| institution | Universiti Malaysia Sabah |
| language | en en |
| publishDate | 2022 |
| publisher | MDPI |
| record_format | eprints |
| spelling | my.ums.eprints-352322023-03-23T02:12:51Z https://eprints.ums.edu.my/id/eprint/35232/ COVID-19 Treatment—Current Status, Advances, and Gap Chian Ho Lee, Ping Chin RA643-645 Disease (Communicable and noninfectious) and public health RA648.5-767 Epidemics. Epidemiology. Quarantine. Disinfection COVID-19, which emerged in December 2019, was declared a global pandemic by the World Health Organization (WHO) in March 2020. The disease was caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It has caused millions of deaths worldwide and caused social and economic disruption. While clinical trials on therapeutic drugs are going on in an Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) public–private partnership collaboration, current therapeutic approaches and options to counter COVID-19 remain few. Therapeutic drugs include the FDA-approved antiviral drugs, Remdesivir, and an immune modulator, Baricitinib. Hence, therapeutic approaches and alternatives for COVID-19 treatment need to be broadened. This paper discusses efforts in approaches to find treatment for COVID-19, such as inhibiting viral entry and disrupting the virus life cycle, and highlights the gap that needs to be filled in these approaches. MDPI 2022 Article PeerReviewed text en https://eprints.ums.edu.my/id/eprint/35232/1/Abstract.pdf text en https://eprints.ums.edu.my/id/eprint/35232/2/Full%20text.pdf Chian Ho and Lee, Ping Chin (2022) COVID-19 Treatment—Current Status, Advances, and Gap. Pathogens, 11. pp. 1-15. ISSN 2076-0817 https://www.mdpi.com/2076-0817/11/10/1201 https://doi.org/10.3390/pathogens11101201 https://doi.org/10.3390/pathogens11101201 |
| spellingShingle | RA643-645 Disease (Communicable and noninfectious) and public health RA648.5-767 Epidemics. Epidemiology. Quarantine. Disinfection Chian Ho Lee, Ping Chin COVID-19 Treatment—Current Status, Advances, and Gap |
| title | COVID-19 Treatment—Current Status, Advances, and Gap |
| title_full | COVID-19 Treatment—Current Status, Advances, and Gap |
| title_fullStr | COVID-19 Treatment—Current Status, Advances, and Gap |
| title_full_unstemmed | COVID-19 Treatment—Current Status, Advances, and Gap |
| title_short | COVID-19 Treatment—Current Status, Advances, and Gap |
| title_sort | covid-19 treatment—current status, advances, and gap |
| topic | RA643-645 Disease (Communicable and noninfectious) and public health RA648.5-767 Epidemics. Epidemiology. Quarantine. Disinfection |
| url | https://eprints.ums.edu.my/id/eprint/35232/1/Abstract.pdf https://eprints.ums.edu.my/id/eprint/35232/2/Full%20text.pdf https://eprints.ums.edu.my/id/eprint/35232/ https://www.mdpi.com/2076-0817/11/10/1201 https://doi.org/10.3390/pathogens11101201 https://doi.org/10.3390/pathogens11101201 |
| url_provider | http://eprints.ums.edu.my/ |